APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Vector Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant Vector Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchRecombinant Vector Vaccines Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Vector Vaccines Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Recombinant Vector Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Vector Vaccines Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Vector Vaccines Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Recombinant Vector Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., CNBG, SINOVAC BIOTECH, Zhifei, GSK, Hualan Bio, ChengDa Bio, NuoCheng Bio and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Recombinant Vector Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Vector Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Vector Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Recombinant Vector Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant Vector Vaccines Segment by Company

SANOFI PASTEUR S.A.

CNBG

SINOVAC BIOTECH

Zhifei

GSK

Hualan Bio

ChengDa Bio

NuoCheng Bio

Novartis

Kangtai

Changsheng Life

Recombinant Vector Vaccines Segment by Type

Varicella

Influenza

Hepatitis

Pneumococcal

Pertussis, Diphtheria, tetanus

Others

Recombinant Vector Vaccines Segment by Application

For Adult

For Child

Recombinant Vector Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vector Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vector Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vector Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Recombinant Vector Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Recombinant Vector Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Recombinant Vector Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Recombinant Vector Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Recombinant Vector Vaccines Industry Trends Table 2. Recombinant Vector Vaccines Industry Drivers Table 3. Recombinant Vector Vaccines Industry Opportunities and Challenges Table 4. Recombinant Vector Vaccines Industry Restraints Table 5. Global Recombinant Vector Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Recombinant Vector Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Recombinant Vector Vaccines Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Recombinant Vector Vaccines Sales Market Share by Manufacturers Table 9. Global Recombinant Vector Vaccines Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Recombinant Vector Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Recombinant Vector Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Recombinant Vector Vaccines Manufacturers, Product Type & Application Table 13. Global Recombinant Vector Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Recombinant Vector Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Varicella Table 17. Major Manufacturers of Influenza Table 18. Major Manufacturers of Hepatitis Table 19. Major Manufacturers of Pneumococcal Table 20. Major Manufacturers of Pertussis, Diphtheria, tetanus Table 21. Major Manufacturers of Others Table 22. Global Recombinant Vector Vaccines Sales by Type 2021 VS 2025 VS 2032 (k units) Table 23. Global Recombinant Vector Vaccines Sales by Type (2021-2026) & (k units) Table 24. Global Recombinant Vector Vaccines Sales by Type (2027-2032) & (k units) Table 25. Global Recombinant Vector Vaccines Sales Market Share by Type (2021-2026) Table 26. Global Recombinant Vector Vaccines Sales Market Share by Type (2027-2032) Table 27. Global Recombinant Vector Vaccines Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 28. Global Recombinant Vector Vaccines Revenue by Type (2021-2026) & (k units) Table 29. Global Recombinant Vector Vaccines Revenue by Type (2027-2032) & (k units) Table 30. Global Recombinant Vector Vaccines Revenue Market Share by Type (2021-2026) Table 31. Global Recombinant Vector Vaccines Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of For Adult Table 33. Major Manufacturers of For Child Table 34. Global Recombinant Vector Vaccines Sales by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Recombinant Vector Vaccines Sales by Application (2021-2026) & (k units) Table 36. Global Recombinant Vector Vaccines Sales by Application (2027-2032) & (k units) Table 37. Global Recombinant Vector Vaccines Sales Market Share by Application (2021-2026) Table 38. Global Recombinant Vector Vaccines Sales Market Share by Application (2027-2032) Table 39. Global Recombinant Vector Vaccines Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 40. Global Recombinant Vector Vaccines Revenue by Application (2021-2026) & (k units) Table 41. Global Recombinant Vector Vaccines Revenue by Application (2027-2032) & (k units) Table 42. Global Recombinant Vector Vaccines Revenue Market Share by Application (2021-2026) Table 43. Global Recombinant Vector Vaccines Revenue Market Share by Application (2027-2032) Table 44. Global Recombinant Vector Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Recombinant Vector Vaccines Sales by Region (2021-2026) & (k units) Table 46. Global Recombinant Vector Vaccines Sales Market Share by Region (2021-2026) Table 47. Global Recombinant Vector Vaccines Sales Forecasted by Region (2027-2032) & (k units) Table 48. Global Recombinant Vector Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Recombinant Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. North America Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 51. North America Recombinant Vector Vaccines Sales by Country (2027-2032) & (k units) Table 52. Europe Recombinant Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Europe Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 54. Europe Recombinant Vector Vaccines Sales by Country (2027-2032) & (k units) Table 55. Asia Pacific Recombinant Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Asia Pacific Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 57. Asia Pacific Recombinant Vector Vaccines Sales by Country (2027-2032) & (k units) Table 58. South America, Middle East and Africa Recombinant Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. South America, Middle East and Africa Recombinant Vector Vaccines Sales by Country (2021-2026) & (k units) Table 60. South America, Middle East and Africa Recombinant Vector Vaccines Sales by Country (2027-2032) & (k units) Table 61. Global Recombinant Vector Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Recombinant Vector Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Recombinant Vector Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Recombinant Vector Vaccines Revenue Market Share by Region (2021-2026) Table 65. Global Recombinant Vector Vaccines Revenue Market Share by Region (2027-2032) Table 66. SANOFI PASTEUR S.A. Company Information Table 67. SANOFI PASTEUR S.A. Business Overview Table 68. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio Table 70. SANOFI PASTEUR S.A. Recent Development Table 71. CNBG Company Information Table 72. CNBG Business Overview Table 73. CNBG Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. CNBG Recombinant Vector Vaccines Product Portfolio Table 75. CNBG Recent Development Table 76. SINOVAC BIOTECH Company Information Table 77. SINOVAC BIOTECH Business Overview Table 78. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio Table 80. SINOVAC BIOTECH Recent Development Table 81. Zhifei Company Information Table 82. Zhifei Business Overview Table 83. Zhifei Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Zhifei Recombinant Vector Vaccines Product Portfolio Table 85. Zhifei Recent Development Table 86. GSK Company Information Table 87. GSK Business Overview Table 88. GSK Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. GSK Recombinant Vector Vaccines Product Portfolio Table 90. GSK Recent Development Table 91. Hualan Bio Company Information Table 92. Hualan Bio Business Overview Table 93. Hualan Bio Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Hualan Bio Recombinant Vector Vaccines Product Portfolio Table 95. Hualan Bio Recent Development Table 96. ChengDa Bio Company Information Table 97. ChengDa Bio Business Overview Table 98. ChengDa Bio Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. ChengDa Bio Recombinant Vector Vaccines Product Portfolio Table 100. ChengDa Bio Recent Development Table 101. NuoCheng Bio Company Information Table 102. NuoCheng Bio Business Overview Table 103. NuoCheng Bio Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. NuoCheng Bio Recombinant Vector Vaccines Product Portfolio Table 105. NuoCheng Bio Recent Development Table 106. Novartis Company Information Table 107. Novartis Business Overview Table 108. Novartis Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Novartis Recombinant Vector Vaccines Product Portfolio Table 110. Novartis Recent Development Table 111. Kangtai Company Information Table 112. Kangtai Business Overview Table 113. Kangtai Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Kangtai Recombinant Vector Vaccines Product Portfolio Table 115. Kangtai Recent Development Table 116. Changsheng Life Company Information Table 117. Changsheng Life Business Overview Table 118. Changsheng Life Recombinant Vector Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Changsheng Life Recombinant Vector Vaccines Product Portfolio Table 120. Changsheng Life Recent Development Table 121. Key Raw Materials Table 122. Raw Materials Key Suppliers Table 123. Recombinant Vector Vaccines Distributors List Table 124. Recombinant Vector Vaccines Customers List Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Recombinant Vector Vaccines Product Image Figure 2. Global Recombinant Vector Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Vector Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Vector Vaccines Sales (2021-2032) & (k units) Figure 5. Global Recombinant Vector Vaccines Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Recombinant Vector Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Varicella Image Figure 9. Influenza Image Figure 10. Hepatitis Image Figure 11. Pneumococcal Image Figure 12. Pertussis, Diphtheria, tetanus Image Figure 13. Others Image Figure 14. Global Recombinant Vector Vaccines Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global Recombinant Vector Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Recombinant Vector Vaccines Sales Market Share by Type (2021-2032) Figure 17. Global Recombinant Vector Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 18. Global Recombinant Vector Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Recombinant Vector Vaccines Revenue Market Share by Type (2021-2032) Figure 20. For Adult Image Figure 21. For Child Image Figure 22. Global Recombinant Vector Vaccines Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Recombinant Vector Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Recombinant Vector Vaccines Sales Market Share by Application (2021-2032) Figure 25. Global Recombinant Vector Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Recombinant Vector Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Recombinant Vector Vaccines Revenue Market Share by Application (2021-2032) Figure 28. North America Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 29. North America Recombinant Vector Vaccines Sales Market Share by Country (2021-2032) Figure 30. U.S. Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 31. Canada Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 32. Mexico Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 33. Europe Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 34. Europe Recombinant Vector Vaccines Sales Market Share by Country (2021-2032) Figure 35. Germany Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 36. France Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 37. U.K. Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 38. Italy Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 39. Netherlands Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 40. Asia Pacific Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 41. Asia Pacific Recombinant Vector Vaccines Sales Market Share by Country (2021-2032) Figure 42. China Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 43. Japan Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 44. South Korea Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 45. Southeast Asia Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 46. India Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 47. Australia Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 48. South America, Middle East and Africa Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 49. South America, Middle East and Africa Recombinant Vector Vaccines Sales Market Share by Country (2021-2032) Figure 50. Brazil Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 51. South Africa Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 52. Saudi Arabia Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 53. Turkey Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 54. Argentina Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 55. UAE Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 56. Egypt Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 57. Chile Recombinant Vector Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 58. Global Recombinant Vector Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Recombinant Vector Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Recombinant Vector Vaccines Revenue (2021-2032) & (US$ Million) Figure 61. North America Recombinant Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Recombinant Vector Vaccines Revenue (2021-2032) & (US$ Million) Figure 63. Europe Recombinant Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Recombinant Vector Vaccines Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Recombinant Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Recombinant Vector Vaccines Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Recombinant Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Recombinant Vector Vaccines Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Recombinant Vector Vaccines Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Varicella
  • Influenza
  • Hepatitis
  • Pneumococcal
  • Pertussis, Diphtheria, tetanus
  • Others
Applications
  • For Adult
  • For Child
Companies covered
  • SANOFI PASTEUR S.A.
  • CNBG
  • SINOVAC BIOTECH
  • Zhifei
  • GSK
  • Hualan Bio
  • ChengDa Bio
  • NuoCheng Bio
  • Novartis
  • Kangtai
  • Changsheng Life

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Vector Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Vector Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Recombinant Vector Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Recombinant Vector Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Recombinant Vector Vaccines Market Dynamics
  1. 2.1 Recombinant Vector Vaccines Industry Trends
  2. 2.2 Recombinant Vector Vaccines Industry Drivers
  3. 2.3 Recombinant Vector Vaccines Industry Opportunities and Challenges
  4. 2.4 Recombinant Vector Vaccines Industry Restraints
3 Recombinant Vector Vaccines Market by Manufacturers
  1. 3.1 Global Recombinant Vector Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Recombinant Vector Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global Recombinant Vector Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Recombinant Vector Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Recombinant Vector Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Recombinant Vector Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global Recombinant Vector Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Recombinant Vector Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Recombinant Vector Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Recombinant Vector Vaccines Tier 1, Tier 2, and Tier 3
4 Recombinant Vector Vaccines Market by Type
  1. 4.1 Recombinant Vector Vaccines Type Introduction
  2. 4.1.1 Varicella
  3. 4.1.2 Influenza
  4. 4.1.3 Hepatitis
  5. 4.1.4 Pneumococcal
  6. 4.1.5 Pertussis, Diphtheria, tetanus
  7. 4.1.6 Others
  8. 4.2 Global Recombinant Vector Vaccines Sales by Type
  9. 4.2.1 Global Recombinant Vector Vaccines Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Recombinant Vector Vaccines Sales by Type (2021-2032)
  11. 4.2.3 Global Recombinant Vector Vaccines Sales Market Share by Type (2021-2032)
  12. 4.3 Global Recombinant Vector Vaccines Revenue by Type
  13. 4.3.1 Global Recombinant Vector Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Recombinant Vector Vaccines Revenue by Type (2021-2032)
  15. 4.3.3 Global Recombinant Vector Vaccines Revenue Market Share by Type (2021-2032)
5 Recombinant Vector Vaccines Market by Application
  1. 5.1 Recombinant Vector Vaccines Application Introduction
  2. 5.1.1 For Adult
  3. 5.1.2 For Child
  4. 5.2 Global Recombinant Vector Vaccines Sales by Application
  5. 5.2.1 Global Recombinant Vector Vaccines Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Recombinant Vector Vaccines Sales by Application (2021-2032)
  7. 5.2.3 Global Recombinant Vector Vaccines Sales Market Share by Application (2021-2032)
  8. 5.3 Global Recombinant Vector Vaccines Revenue by Application
  9. 5.3.1 Global Recombinant Vector Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Recombinant Vector Vaccines Revenue by Application (2021-2032)
  11. 5.3.3 Global Recombinant Vector Vaccines Revenue Market Share by Application (2021-2032)
6 Global Recombinant Vector Vaccines Sales by Region
  1. 6.1 Global Recombinant Vector Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Vector Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Recombinant Vector Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global Recombinant Vector Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Recombinant Vector Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Recombinant Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Recombinant Vector Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Recombinant Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Recombinant Vector Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Recombinant Vector Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Recombinant Vector Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Recombinant Vector Vaccines Revenue by Region
  1. 7.1 Global Recombinant Vector Vaccines Revenue by Region
  2. 7.1.1 Global Recombinant Vector Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Recombinant Vector Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global Recombinant Vector Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global Recombinant Vector Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Recombinant Vector Vaccines Revenue (2021-2032)
  8. 7.2.2 North America Recombinant Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Recombinant Vector Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe Recombinant Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Recombinant Vector Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Recombinant Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Recombinant Vector Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Recombinant Vector Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 SANOFI PASTEUR S.A.
  2. 8.1.1 SANOFI PASTEUR S.A. Company Information
  3. 8.1.2 SANOFI PASTEUR S.A. Business Overview
  4. 8.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
  6. 8.1.5 SANOFI PASTEUR S.A. Recent Developments
  7. 8.2 CNBG
  8. 8.2.1 CNBG Company Information
  9. 8.2.2 CNBG Business Overview
  10. 8.2.3 CNBG Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CNBG Recombinant Vector Vaccines Product Portfolio
  12. 8.2.5 CNBG Recent Developments
  13. 8.3 SINOVAC BIOTECH
  14. 8.3.1 SINOVAC BIOTECH Company Information
  15. 8.3.2 SINOVAC BIOTECH Business Overview
  16. 8.3.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
  18. 8.3.5 SINOVAC BIOTECH Recent Developments
  19. 8.4 Zhifei
  20. 8.4.1 Zhifei Company Information
  21. 8.4.2 Zhifei Business Overview
  22. 8.4.3 Zhifei Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Zhifei Recombinant Vector Vaccines Product Portfolio
  24. 8.4.5 Zhifei Recent Developments
  25. 8.5 GSK
  26. 8.5.1 GSK Company Information
  27. 8.5.2 GSK Business Overview
  28. 8.5.3 GSK Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GSK Recombinant Vector Vaccines Product Portfolio
  30. 8.5.5 GSK Recent Developments
  31. 8.6 Hualan Bio
  32. 8.6.1 Hualan Bio Company Information
  33. 8.6.2 Hualan Bio Business Overview
  34. 8.6.3 Hualan Bio Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hualan Bio Recombinant Vector Vaccines Product Portfolio
  36. 8.6.5 Hualan Bio Recent Developments
  37. 8.7 ChengDa Bio
  38. 8.7.1 ChengDa Bio Company Information
  39. 8.7.2 ChengDa Bio Business Overview
  40. 8.7.3 ChengDa Bio Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ChengDa Bio Recombinant Vector Vaccines Product Portfolio
  42. 8.7.5 ChengDa Bio Recent Developments
  43. 8.8 NuoCheng Bio
  44. 8.8.1 NuoCheng Bio Company Information
  45. 8.8.2 NuoCheng Bio Business Overview
  46. 8.8.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
  48. 8.8.5 NuoCheng Bio Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis Recombinant Vector Vaccines Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Kangtai
  56. 8.10.1 Kangtai Company Information
  57. 8.10.2 Kangtai Business Overview
  58. 8.10.3 Kangtai Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kangtai Recombinant Vector Vaccines Product Portfolio
  60. 8.10.5 Kangtai Recent Developments
  61. 8.11 Changsheng Life
  62. 8.11.1 Changsheng Life Company Information
  63. 8.11.2 Changsheng Life Business Overview
  64. 8.11.3 Changsheng Life Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Changsheng Life Recombinant Vector Vaccines Product Portfolio
  66. 8.11.5 Changsheng Life Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Recombinant Vector Vaccines Value Chain Analysis
  2. 9.1.1 Recombinant Vector Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Recombinant Vector Vaccines Production Mode & Process
  6. 9.2 Recombinant Vector Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Recombinant Vector Vaccines Distributors
  9. 9.2.3 Recombinant Vector Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst